

# Serotonergic influences on locomotor circuits

Urszula Sławińska<sup>1,3</sup> and Larry M Jordan<sup>2,3</sup>

Serotonin (5-HT) neurons can be activated from the Mesencephalic Locomotor Region (MLR) to produce release of 5-HT in the spinal cord, and MLR evoked locomotion can be blocked by a 5-HT<sub>7</sub> receptor antagonist. 5-HT control shifts during development from control of coordinating interneurons in neonates to influences on afferent input in adults. Pharmacotherapy involving 5-HT receptor agonists has progressed to clinical trials on human subjects with spinal cord injury (SCI). Work on plasticity of the 5-HT system shows that SCI results in changes in 5-HT receptor protein and mRNA, and that these changes can be reversed by exercise or by replacement of 5-HT with intraspinal grafts. Recent data on cross-talk and heterodimerization of these receptors suggest new mechanisms for plasticity.

## Addresses

<sup>1</sup> Nencki Institute of Experimental Biology of Polish Academy of Sciences, Poland

<sup>2</sup> University of Manitoba, Department of Physiology, Winnipeg, Canada

Corresponding authors:

Sławińska, Urszula ([u.slawinska@nencki.gov.pl](mailto:u.slawinska@nencki.gov.pl)),

Jordan, Larry M ([larry@srcr.umanitoba.ca](mailto:larry@srcr.umanitoba.ca))

<sup>3</sup> Both the authors contributed equally to this work.

**Current Opinion in Physiology** 2019, **8**:63–69

This review comes from a themed issue on **Motor control systems**

Edited by **Gareth B Miles** and **Claire Wyart**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 2nd January 2019

<https://doi.org/10.1016/j.cophys.2018.12.012>

2468-8673/© 2019 Elsevier Ltd. All rights reserved.

## Basic mechanisms of serotonergic motor control in mammals


The importance of serotonin in the control of locomotion has been emphasized in recent reviews [1,2,3<sup>\*</sup>,4,5,6<sup>\*</sup>]. Serotonergic pathways are included in the reticulospinal (RS) pathways activated by the locomotor signals from higher structures of the brain. The RS neurons are activated by the Mesencephalic Locomotor Region (MLR), which includes the cuneiform nucleus (CnF), the pedunculopontine nucleus (PPN), and surrounding structures, and which receives input and control from forebrain as well as diencephalic, limbic and basal ganglia structures which engage the midbrain locomotor areas for the full range of locomotor tasks. We have summarized the 5-HT system involved in locomotor control in [Figure 1](#). Recent evidence

shows that the 5-HT RS neurons are activated when locomotion is initiated by MLR stimulation. Noga and Opris [7] demonstrated in cats that monoaminergic neurons located in the nuclei of origin of descending serotonergic pathways innervating the spinal cord are activated during MLR-evoked locomotion. Locomotion induced by MLR stimulation resulted in the expression of the activity-dependent marker Fos in 5-HT neurons of nucleus raphe magnus (RMg) and the Parapyramidal Region (PPR) of the medulla [7]. In rats a component of the MLR (CnF) projects to descending 5-HT neurons in the medulla [8–11], whereas evidence for such a projection from PPN is less clear. CnF has recently been shown to be the main component of the MLR for inducing locomotion in mice [12<sup>\*\*</sup>]. Josset *et al.* [12<sup>\*\*</sup>] found that photostimulation of glutamatergic CnF neurons initiate and accelerate locomotion, whereas glutamatergic and cholinergic PPN contribute to slow-walking gaits and locomotor arrests. Other recent studies using genetic tools in mice have also implicated the CnF, but show evidence for a greater role for PPN neurons [13,14]. These studies confirm work in the cat model, which implicate the CnF as the effective site for producing locomotion [15<sup>\*</sup>]. Stimulation of the MLR results in release of 5-HT in the cat spinal cord [16<sup>\*</sup>]. This is direct evidence that MLR stimulation activates descending 5-HT neurons. Other recent evidence supporting this conclusion is provided by the fact that voluntary locomotion in intact adult rats and fictive locomotion induced by MLR stimulation in adult decerebrate rats is blocked by an intrathecal 5-HT<sub>7</sub> receptor antagonist [17]. In contrast to neonatal animals, in adult rats there is no effect on coordinating interneurons by this receptor, but the effect is mediated by this receptor shifts during development [18] to influences on afferent input. These studies support previous findings that locomotion is associated with 5-HT release in the spinal cord of rats [19,20], 5-HT and its agonists can produce locomotion [21–23], and 5-HT neurons grafted into the spinal cord facilitate locomotion [24–28]. We suggest that MLR activation of descending 5-HT neurons of the medulla normally occurs when locomotion is initiated, resulting in CPG activation involving 5-HT<sub>7</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>1A</sub> receptors ([Figure 1](#)).

## The role of 5-HT receptors in locomotor control

The important role played by 5-HT in the initiation of locomotion has been advanced by extensive research efforts using isolated neonatal rodent preparations (reviewed in Refs. [23,29–32]). The descending 5-HT neurons in B1–B3 appear to be recruited during activation of the brainstem locomotor region ([Figure 1](#)), and

Figure 1



Schematic view of neuronal projections from the MLR toward the serotonergic raphe nuclei (ROb—raphe obscurus; RPa—raphe pallidus; RMg—raphe magnus) and the PPR (Parapyramidal Region). Axons of serotonergic (5-HT) neurons descend via the ventrolateral funiculus (VLF) to innervate lumbar spinal locomotor interneurons comprising the central pattern generator (CPG) and lumbar motoneurons (MNs) and via DLF to innervate dorsal horn interneurons. Schematic drawing of brain and spinal cross-sections based on Paxinos 1995 'The rat Nervous system' 2nd edition [83]. Receptor distribution is based on observations in the Jordan lab as well as the Stawińska lab [17,23,84].

stimulation of 5-HT neurons in the medulla elicits locomotion in isolated rat brainstem and spinal cord preparations [18] that is blocked by spinal application of 5-HT antagonists. Husch *et al.* have developed a means of studying fictive locomotion *in vitro* using perforated patch [33], and they went on to show intrinsic properties and serotonergic modulation of commissural interneurons (CINs) change during postnatal development in mice so that by P14–16, when mature walking emerges, serotonin can induce plateau potential capability [34]. Genetically identified V2a locomotor neurons display intrinsic membrane potential bistability in adult mice [35] but not in younger animals. Thus, the properties of neurons examined in neonatal rodent preparations may not be typical of what happens in adult animals (see Refs. [17,36]).

Constitutively active 5-HT<sub>2C</sub> receptors (active in the absence of 5-HT) in rat motoneurons, which emerge after SCI, have been implicated in the recovery of locomotion after injury [37,38]. A neutral antagonist of 5-HT<sub>2C</sub> receptors was unable to block this effect, but an inverse agonist was effective. This is a feature of constitutive activity, which appears due to plasticity after chronic SCI. This is also suggested to account for the emergence of spasticity

after SCI. It has also been suggested that the appearance of increased numbers of interneurons expressing AADC (Aromatic L-Amino Acid Decarboxylase Cells), which can produce 5-HT when exogenous 5-HT precursors are available [39–41], normalizes 5-HT function after SCI.

A role for 5-HT<sub>1A</sub> receptors in the control of locomotion is supported by numerous studies on rats using 8-OH-DPAT, which has affinity for both 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptors [21–23,42,43]. A clear demonstration of the contribution of 5-HT<sub>1A</sub> receptors to locomotor-like activity was carried out by Landry *et al.* [44], who showed 8-OH-DPAT produced locomotor-like activity in the spinal cord of 5-HT<sub>7</sub> receptor knockout mice. Some cat spinal interneurons that are active during locomotion possess 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptors [45]. The interest in the ability of these 5-HT receptors to induce locomotion after spinal cord injury has led to recent attempts to use the 5-HT receptor agonist Buspirone in human subjects with spinal cord injury [46–48]. Buspirone has been shown to facilitate locomotor recovery in spinal mice [49] in combination with training. The precise mode of action of Buspirone in these cases is uncertain, because it is an agonist of 5-HT<sub>1A</sub>, 5-HT<sub>2</sub> and 5-HT<sub>7</sub> receptors

[46,49,50]. Spinalon™ is a therapy based on the 5-HT agonist Bupirone with additional components (carbidopa/levodopa) that has been tested recently for efficacy and safety [6,50,51]. However, the results of Spinalon™ treatment are ambiguous because 66% patients did not respond to treatment even if in the other completely paralyzed individuals promising improvement of rhythmic leg activity was observed [51]. Efforts to enhance the efficacy of pharmacological therapy using other modalities of treatment, including locomotor training and epidural stimulation, have been recently reviewed [6,50].

## Serotonergic plasticity related to locomotor recovery after SCI

### Sprouting of 5-HT fibers

It is uncertain what contribution 5-HT makes to the control of locomotion in humans, but extensive recent research in rodents has provided an appreciation of the importance of 5-HT in these species. Of particular interest are recent studies that show a strong correlation between recovery of locomotor function and the presence of 5-HT fibers and terminals in the lumbar cord [52–55]. Included in some of these studies is the fact that locomotor training or exercise promotes pro-locomotor plasticity in the 5-HT system.

### Upregulation of 5-HT receptors

A consideration of the contribution of 5-HT receptors to the recovery of locomotor function after injury requires attention to the injury-induced plasticity. Considerable interest has been focused on upregulation of specific 5-HT receptors in rats, including, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub> or alternative splicing of 5-HT<sub>2C</sub> [37,43,56]. All of these receptors are implicated in the control of locomotion (reviewed in Refs. [2,57]).

Activation of spinal 5-HT<sub>1A</sub> receptors is thought to facilitate locomotion in rodents [3,44], and upregulation of 5-HT<sub>1A</sub> receptors after spinal cord injury is a prominent feature of the response to spinal cord injury [43,56]. The upregulation in 5-HT<sub>1A</sub> receptors following spinal cord transection does not occur when the cord is also 'isolated' (deafferented), suggesting a role for afferents from the limb in the expression of these receptors [43]. The significant role of afferents from the limb was demonstrated in upright walking in spinal rats [58]. Considering that 5-HT<sub>1A/7</sub> agonists (8-OH-DPAT) improve locomotion in the horizontal posture but impair locomotion in the upright posture, it can be suggested that a proper balance of afferent feedback from the foot and descending supraspinal inputs through 5-HT<sub>1A/5-HT<sub>7</sub></sub> receptor activation is necessary for optimal locomotor recovery [58].

Upregulation of 5-HT receptors after SCI in rats has been confirmed recently by Ganzer *et al.* [56], who demonstrated that 5-HT pharmacotherapy (quipazine and 8-

OH-DPAT) and bike exercise normalized 5-HT receptors (5-HT<sub>2A</sub>, 5-HT<sub>1A</sub>) and dendritic atrophy after SCI. Further research has focused on SCI and exercise [59] or restoration of 5-HT innervation [60] effects on receptor mRNA in motoneurons of rat hindlimb muscles. It was demonstrated that graft origin 5-HT innervation in the spinal cord of paraplegic rats could reverse changes in gene expression of 5-HT<sub>2A</sub> and 5-HT<sub>7</sub> receptors induced by SCI in motoneurons innervating hindlimb muscles but not those innervating tail muscles [60].

### 5-HT<sub>2A</sub> receptors control of K<sup>+</sup>-Cl<sup>-</sup> cotransporter (KCC2)

5-HT<sub>2A</sub> receptors are implicated in the control of KCC2, the main Cl<sup>-</sup> extruder in mature rat neurons [61]. It is known that KCC2 is responsible for maintaining the intracellular chloride concentration. Downregulation of KCC2 induced by spinal cord injury in rats, particularly in motoneuron membranes, causes a reduction of the strength of postsynaptic inhibition by depolarizing the Cl<sup>-</sup> equilibrium potential [62]. Vinay's group demonstrated that activation of 5-HT<sub>2A</sub> receptors in paraplegic rats, which hyperpolarizes the reversal potential of inhibitory postsynaptic potentials (IPSPs), increases the cell membrane expression of KCC2 and restores endogenous inhibition [61]. Tashiro *et al.* demonstrated that treadmill training that upregulated endogenous brain-derived neurotrophic factor (BDNF) expression also induced post-translational modification of KCC2 in the rat lumbar enlargement [63]. Thus, neural plasticity expressed in the upregulation of KCC2 induced by activation of 5-HT<sub>2A</sub> receptors or by treadmill training, has therapeutic potential in the treatment of altered chloride homeostasis and may provide a new strategy for functional rehabilitation of locomotor movements.

### Spasticity—an effect of hyperexcitability as a result of post-injury plasticity

Motoneuron excitability after SCI is regulated not only by restoring endogenous inhibition via the 5-HT<sub>2A</sub> receptor but by upregulation of the constitutively active unedited form of the 5-HT<sub>2C</sub> receptor [37]. Tysseling *et al.* [64] showed that constitutively active 5-HT<sub>2C</sub> contributes to reflex hyperexcitability of sacral segments of spinal cord in mice with incomplete chronic thoracic spinal cord injury in *in vitro* conditions. However, their *in vivo* investigations in these same mice did not include tests of constitutive activity of 5-HT<sub>2C</sub> receptors on reflexes induced by electrical stimulation of the plantar surface of the hind paw. These hind limb reflexes were not significantly modulated by SSRI or baclofen treatment, showing the increased amplitude after partial SCI was not altered by increased the release of 5-HT or by increased inhibition. This would be consistent with constitutive activity of 5-HT receptors on hind limb motoneurons, but further experiments will be necessary to determine whether any excitability changes detected in limb motoneurons is due to plasticity in 5-HT<sub>2C</sub> receptors, because the effects of a

neutral antagonist and an inverse agonist of 5-HT<sub>2C</sub> receptors were attempted only on reflexes in isolated sacral spinal cords from the same animals. Recent data [65] revealed that excitatory spinal interneurons are recruited by sensory input to generate persistent neural activity after sacral SCI. In our experiments, tail and limb motoneurons respond differently to chronic SCI with regard to changes in 5-HT gene expression [60]. These experiments raise new questions about the detailed forms of plasticity induced by chronic SCI, and point out that constitutive activity of 5-HT receptors in motoneurons (see Ref. [66]) is not the sole basis for altered 5-HT action.

### Crosstalk as a mechanism of neural plasticity

Interest in intermittent hypoxia (IH) as a means of enhancing functional recovery after spinal cord injury has been prompted by findings on the control of phrenic motoneurons after spinal cord injury. IH triggers episodic serotonin release near motoneurons, activating serotonin receptors and triggering a cellular cascade leading to increased BDNF synthesis, TrkB activation, and downstream events that enhance synaptic inputs to relevant motoneurons. Crosstalk between 5HT<sub>2A</sub> and 5-HT<sub>7</sub> receptors occurs such that 5-HT<sub>7</sub> receptor activation can suppress the 5-HT<sub>2A</sub> mediated response to intermittent hypoxia in rats [67–69]. Recent clinical trials in patients have revealed that IH can be effective in enhancing locomotor recovery after SCI [70\*]. Further work is needed to determine the role, if any, of serotonin in the effect of IH on walking.

### Potential role of 5-HT receptor heterodimerization

Recently, a considerable body of evidence indicates that cross-talk interactions between various 5-HT receptors can contribute to the regulation of various physiological functions, normally and in pathology [71,72]. One pair of such receptors are 5-HT<sub>1A</sub> and 5-HT<sub>7</sub>, which can form heterodimers *in vitro* and *in vivo* [73]. This results in the weakening of Gi-protein activation mediated by 5-HT<sub>1A</sub> receptors, whereas the functions of 5-HT<sub>7</sub> are not significantly affected. There are data demonstrating a critical role of these receptors in control of locomotion in mammals, so it is possible that the heterodimer structure is involved in locomotor function as well. Our recent investigations demonstrated that using 8-OH-DPAT (agonist of 5-HT<sub>1A/7</sub> receptors) is more effective in enhancing recovery of locomotor function in paraplegic rats than LP211 (agonist of 5-HT<sub>7</sub> receptors; gift from Marcello Leopoldo). Activation of both receptors together with 8-OH-DPAT has a more potent effect on locomotion induction than activation of 5-HT<sub>7</sub> receptors alone (preliminary observation), suggesting that some interaction between these receptors may occur. If they form heterodimers then the activation of 5-HT<sub>7</sub> receptors may alter the efficacy of 5-HT<sub>1A</sub> receptors as was shown in other pathological conditions [72,74,75].

It is known that 5-HT<sub>1A</sub> receptors play an important role in the regulation of neuronal development and plasticity [72]. 5-HT<sub>7</sub> receptors are involved in the posttranscriptional regulation of the functional state of 5-HT<sub>1A</sub> receptors [71]. It is also known that 5-HT<sub>1A</sub> receptors seem to be regulated by the metabotropic 5-HT<sub>2A</sub> receptors [76]. Interplay between 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub> receptors was demonstrated by chronic [77,78] and acute [79,80] activation of 5-HT<sub>2A</sub> receptors, which produced considerable reduction in 5-HT<sub>1A</sub> receptor functional activity in rats. Other receptors important in locomotion that can form heteromers are the 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. For example, colocalization of both 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> is described in phrenic motoneurons of the cervical ventral horn. They are implicated in respiratory recovery following cervical hemisection [81], because 5-HT<sub>2A</sub> receptors suppress the function of 5-HT<sub>2C</sub> receptors. Thus, the interplay of 5-HT<sub>7</sub>/5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>/5-HT<sub>1A</sub> and/or 5-HT<sub>2A</sub>/5-HT<sub>1A</sub> receptors might be involved in serotonin system plasticity. Such interactions need to be investigated in locomotion.

There are many other examples of interplay between different 5-HT receptors [82] that might be involved in neural plasticity associated with recovery of motor function induced by various rehabilitation strategies. However, this topic remains still controversial and needs to be investigated in more detail.

### Conclusions

Recent evidence supports the hypothesis that 5-HT influences at the spinal level are required for control of locomotion. The 5-HT system is subject to plasticity after injury that can be normalized by activity or cell replacement therapy, and this may be associated with enhancement of locomotor recovery. Previously unknown properties of 5-HT receptors have been revealed, and they may contribute to the normal control of locomotion as well as to the response to spinal cord injury. Knowledge regarding the 5-HT receptors involved in locomotor control has led to clinical trials for restoration of function after injury. Further investigation is needed on all these fronts to maximize our ability to restore locomotion.

### Conflict of interest statement

Nothing declared.

### Acknowledgements

This work was supported by ERA-NET NEURON CoFund Consortium NEURONICHE (The National Centre for Research and Development; ERA-NET-Neuron/16/17) to US as well as by Canadian Paraplegic Association (49032) and CIHR (47526) grants to LMJ.

### References

1. Miles GB, Sillar KT: **Neuromodulation of vertebrate locomotor control networks.** *Physiology (Bethesda)* 2011, **26**:393-411 <http://dx.doi.org/10.1152/physiol.00013.2011>.

2. Ghosh M, Pearse DD: **The role of the serotonergic system in locomotor recovery after spinal cord injury.** *Front Neural Circuits* 2014, **8**:151 <http://dx.doi.org/10.3389/fncir.2014.00151>.
3. Diaz-Rios M, Guertin PA, Rivera-Oliver M: **Neuromodulation of spinal locomotor networks in rodents.** *Curr Pharm Des* 2017, **23**:1741-1752 <http://dx.doi.org/10.2174/1381612823666170124111729>.  
Comprehensive overview providing basic knowledge of the main mechanisms involved in the neuromodulatory control of locomotor activity. They review recent findings addressing the role of neuromodulators such as glutamate, dopamine, serotonin, acetylcholine, and adenosine in eliciting, modulating, and terminating spinal CPG network in rodents.
4. Hofstoetter US, Knikou M, Guertin PA, Minassian K: **Probing the human spinal locomotor circuits by phasic step-induced feedback and by tonic electrical and pharmacological neuromodulation.** *Curr Pharm Des* 2017, **23**:1805-1820 <http://dx.doi.org/10.2174/1381612822666161214144655>.
5. Nardone R, Holler Y, Thomschewski A, Holler P, Lochner P, Golaszewski S, Brigo F, Trinka E: **Serotonergic transmission after spinal cord injury.** *J Neural Transm (Vienna)* 2015, **122**:279-295 <http://dx.doi.org/10.1007/s00702-014-1241-z>.
6. Taccola G, Sayenko D, Gad P, Gerasimenko Y, Edgerton VR: **And yet it moves: recovery of volitional control after spinal cord injury.** *Prog Neurobiol* 2018, **160**:64-81 <http://dx.doi.org/10.1016/j.pneurobio.2017.10.004>.  
Comprehensive review proposing activity-dependent plasticity of spinal and supraspinal networks as a key factor in recovery of volitional sensory-motor function in persons with chronic motor paralysis following SCI. Such a plasticity can be triggered by neuromodulation induced with electrical and pharmacological interventions.
7. Noga BR, Opris I: **The hierarchical circuit for executive control of movement.** In *The Physics of the Mind and Brain Disorders*. Edited by Opris I, Casanova MF. Switzerland: Springer International Publishing; 2017 [http://dx.doi.org/10.1007/978-3-319-29674-6\\_5](http://dx.doi.org/10.1007/978-3-319-29674-6_5). Springer Series in Cognitive and Neural Systems, 2017, Chapter 5.
8. Behbehani MM, Zemlan FP: **Response of nucleus raphe magnus neurons to electrical stimulation of nucleus cuneiformis: role of acetylcholine.** *Brain Res* 1986, **369**:110-118.
9. Bernard JF, Peschanski M, Besson JM: **Afferents and efferents of the rat cuneiformis nucleus: an anatomical study with reference to pain transmission.** *Brain Res* 1989, **490**:181-185.
10. Richter RC, Behbehani MM: **Evidence for glutamic acid as a possible neurotransmitter between the mesencephalic nucleus cuneiformis and the medullary nucleus raphe magnus in the lightly anesthetized rat.** *Brain Res* 1991, **544**:279-286.
11. Korte SM, Jaarsma D, Luiten PG, Bohus B: **Mesencephalic cuneiform nucleus and its ascending and descending projections serve stress-related cardiovascular responses in the rat.** *J Auton Nerv Syst* 1992, **41**:157-176.
12. Josset N, Roussel M, Lemieux M, Lafrance-Zoubga D, Rastqar A, Bretzner F: **Distinct contributions of mesencephalic locomotor region nuclei to locomotor control in the freely behaving mouse.** *Curr Biol* 2018, **28**:884-901.e3 <http://dx.doi.org/10.1016/j.cub.2018.02.007>.  
Optogenetic study on the relative contributions of PPN and CnF to the initiation of locomotion.
13. Caggiano V, Leiras R, Goni-Erro H, Masini D, Ballardita C, Bouvier J, Caldeira V, Fisone G, Kiehn O: **Midbrain circuits that set locomotor speed and gait selection.** *Nature* 2018, **553**:455-460.
14. Roseberry TK, Lee AM, Lalive AL, Wilbrecht L, Bonci A, Kreitzer AC: **Cell-type-specific control of brainstem locomotor circuits by basal ganglia.** *Cell* 2016, **164**:526-537 <http://dx.doi.org/10.1016/j.cell.2015.12.037>.
15. Takakusaki K, Chiba R, Nozu T, Okumura T: **Brainstem control of locomotion and muscle tone with special reference to the role of the mesopontine tegmentum and medullary reticulospinal systems.** *J Neural Transm* 2016, **123**:695-729.  
A thorough differentiation of the effects of CnF and PPN on the control of locomotion in cats.
16. Noga BR, Turkson RP, Xie S, Taberner A, Pinzon A, Hentall ID: **Monoamine release in the cat lumbar spinal cord during fictive locomotion evoked by the mesencephalic locomotor region.** *Front Neural Circuits* 2017, **11**:59 <http://dx.doi.org/10.3389/fncir.2017.00059>.  
*In vivo* voltammetry was used to record the release of 5-HT during stimulation of the MLR to induce locomotion.
17. Cabaj AM, Majczyński H, Couto E, Gardiner PF, Stecina K, Stawińska U, Jordan LM: **Serotonin controls initiation of locomotion and afferent modulation of coordination via 5-HT7 receptors in adult rats.** *J Physiol* 2017, **595**:301-320 <http://dx.doi.org/10.1113/JP272271>.
18. Liu J, Jordan LM: **Stimulation of the parapyramidal region of the neonatal rat brain stem produces locomotor-like activity involving spinal 5-HT7 and 5-HT2A receptors.** *J Neurophysiol* 2005, **94**:1392-1404 <http://dx.doi.org/10.1152/jn.00136.2005>.
19. Gerin C, Privat A: **Direct evidence for the link between monoaminergic descending pathways and motor activity: II. A study with microdialysis probes implanted in the ventral horn of the spinal cord.** *Brain Res* 1998, **794**:169-173.
20. Gerin CG, Hill A, Hill S, Smith K, Privat A: **Serotonin release variations during recovery of motor function after a spinal cord injury in rats.** *Synapse* 2010, **64**:855-861 <http://dx.doi.org/10.1002/syn.20802>.
21. Antri M, Mouffle C, Orsal D, Barthe JY: **5-HT1A receptors are involved in short- and long-term processes responsible for 5-HT-induced locomotor function recovery in chronic spinal rat.** *Eur J Neurosci* 2003, **18**:1963-1972.
22. Antri M, Orsal D, Barthe JY: **Locomotor recovery in the chronic spinal rat: effects of long-term treatment with a 5-HT2 agonist.** *Eur J Neurosci* 2002, **16**:467-476.
23. Stawińska U, Miazga K, Jordan LM: **5-HT(2) and 5-HT(7) receptor agonists facilitate plantar stepping in chronic spinal rats through actions on different populations of spinal neurons.** *Front Neural Circuits* 2014, **8**:95 <http://dx.doi.org/10.3389/fncir.2014.00095>.
24. Yakovlev A, Cabelguen JM, Orsal D, Gimenez y Ribotta M, Rajaofetra N, Drian MJ, Bussel B, Privat A: **Fictive motor activities in adult chronic spinal rats transplanted with embryonic brainstem neurons.** *Exp Brain Res* 1995, **106**:69-78.
25. Feraboli-Lohnherr D, Orsal D, Yakovlev A, Gimenez y Ribotta M, Privat A: **Recovery of locomotor activity in the adult chronic spinal rat after sublesional transplantation of embryonic nervous cells: specific role of serotonergic neurons.** *Exp Brain Res* 1997, **113**:443-454.
26. Ribotta MG, Provencher J, Feraboli-Lohnherr D, Rossignol S, Privat A, Orsal D: **Activation of locomotion in adult chronic spinal rats is achieved by transplantation of embryonic raphe cells reinnervating a precise lumbar level.** *J Neurosci* 2000, **20**:5144-5152.
27. Stawińska U, Majczyński H, Djavadian R: **Recovery of hindlimb motor functions after spinal cord transection is enhanced by grafts of the embryonic raphe nuclei.** *Exp Brain Res* 2000, **132**:27-38.
28. Majczyński H, Maleszak K, Cabaj A, Stawińska U: **Serotonin-related enhancement of recovery of hind limb motor functions in spinal rats after grafting of embryonic raphe nuclei.** *J Neurotrauma* 2005, **22**:590-604 <http://dx.doi.org/10.1089/neu.2005.22.590>.
29. Boulenguez P, Vinay L: **Strategies to restore motor functions after spinal cord injury.** *Curr Opin Neurobiol* 2009, **19**:587-600 <http://dx.doi.org/10.1016/j.conb.2009.10.005>.
30. Kiehn O: **Locomotor circuits in the mammalian spinal cord.** *Annu Rev Neurosci* 2006, **29**:279-306 <http://dx.doi.org/10.1146/annurev.neuro.29.051605.112910>.
31. Perrier JF, Cotel F: **Serotonergic modulation of spinal motor control.** *Curr Opin Neurobiol* 2015, **33**:1-7 <http://dx.doi.org/10.1016/j.conb.2014.12.008>.

32. Schmidt BJ, Jordan LM: **The role of serotonin in reflex modulation and locomotor rhythm production in the mammalian spinal cord.** *Brain Res Bull* 2000, **53**:689-710.
33. Husch A, Cramer N, Harris-Warrick RM: **Long-duration perforated patch recordings from spinal interneurons of adult mice.** *J Neurophysiol* 2011, **106**:2783-2789 <http://dx.doi.org/10.1152/jn.00673.2011>.
34. Abbinanti MD, Zhong G, Harris-Warrick RM: **Postnatal emergence of serotonin-induced plateau potentials in commissural interneurons of the mouse spinal cord.** *J Neurophysiol* 2012, **108**:2191-2202 <http://dx.doi.org/10.1152/jn.00336.2012>.
35. Husch A, Dietz SB, Hong DN, Harris-Warrick RM: **Adult spinal V2a interneurons show increased excitability and serotonin-dependent bistability.** *J Neurophysiol* 2015, **113**:1124-1134 <http://dx.doi.org/10.1152/jn.00741.2014>.
36. Jordan LM, McVagh JR, Noga BR, Cabaj AM, Majczyński H, Stawińska U, Provencher J, Leblond H, Rossignol S: **Cholinergic mechanisms in spinal locomotion-potential target for rehabilitation approaches.** *Front Neural Circuits* 2014, **8**:132 <http://dx.doi.org/10.3389/fncir.2014.00132>.
37. Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico J, Harvey PJ, Li X, Harris RL, Ballou EW, Anelli R et al.: **Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT<sub>2C</sub> receptors.** *Nat Med* 2010, **16**:694-700 <http://dx.doi.org/10.1038/nm.2160>.
38. Fouad K, Rank MM, Vavrek R, Murray KC, Sanelli L, Bennett DJ: **Locomotion after spinal cord injury depends on constitutive activity in serotonin receptors.** *J Neurophysiol* 2010, **104**:2975-2984 <http://dx.doi.org/10.1152/jn.00499.2010>.
39. Wienecke J, Ren LQ, Hultborn H, Chen M, Moller M, Zhang Y, Zhang M: **Spinal cord injury enables aromatic L-amino acid decarboxylase cells to synthesize monoamines.** *J Neurosci* 2014, **34**:11984-12000 <http://dx.doi.org/10.1523/JNEUROSCI.3838-13.2014>.
40. Ren LQ, Chen M, Hultborn H, Guo S, Zhang Y, Zhang M: **Heterogenic distribution of aromatic L-amino acid decarboxylase neurons in the rat spinal cord.** *Front Integr Neurosci* 2017, **11**:31 <http://dx.doi.org/10.3389/fnint.2017.00031>.
41. Zhang M: **Aromatic L-amino acid decarboxylase cells in the spinal cord: a potential origin of monoamines.** *Neural Regen Res* 2015, **10**:715-717 <http://dx.doi.org/10.4103/1673-5374.156960>.
42. Antri M, Barthe JY, Mouffle C, Orsal D: **Long-lasting recovery of locomotor function in chronic spinal rat following chronic combined pharmacological stimulation of serotonergic receptors with 8-OHDPAT and quipazine.** *Neurosci Lett* 2005, **384**:162-167 <http://dx.doi.org/10.1016/j.neulet.2005.04.062>.
43. Otsu CK, Walwyn WM, Tillakaratne NJ, Zhong H, Roy RR, Edgerton VR: **Distribution and localization of 5-HT<sub>1A</sub> receptors in the rat lumbar spinal cord after transection and deafferentation.** *J Neurotrauma* 2009, **26**:575-584 <http://dx.doi.org/10.1089/neu.2008.0640>.
44. Landry ES, Lapointe NP, Rouillard C, Levesque D, Hedlund PB, Guertin PA: **Contribution of spinal 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord-transected mice.** *Eur J Neurosci* 2006, **24**:535-546 <http://dx.doi.org/10.1111/j.1460-9568.2006.04917.x>.
45. Noga BR, Johnson DM, Riesgo MI, Pinzon A: **Locomotor-activated neurons of the cat. I. Serotonergic innervation and co-localization of 5-HT<sub>7</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>1A</sub> receptors in the thoraco-lumbar spinal cord.** *J Neurophysiol* 2009, **102**:1560-1576 <http://dx.doi.org/10.1152/jn.91179.2008>.
46. Moshonkina TR, Shapkova EY, Sukhotina IA, Emeljannikov DV, Gerasimenko YP: **Effect of combination of non-invasive spinal cord electrical stimulation and serotonin receptor activation in patients with chronic spinal cord lesion.** *Bull Exp Biol Med* 2016, **161**:749-754 <http://dx.doi.org/10.1007/s10517-016-3501-4>.
47. Gerasimenko Y, Gorodnichev R, Moshonkina T, Sayenko D, Gad P, Reggie Edgerton V: **Transcutaneous electrical spinal-cord stimulation in humans.** *Ann Phys Rehabil Med* 2015, **58**:225-231 <http://dx.doi.org/10.1016/j.rehab.2015.05.003>.
48. Gad P, Gerasimenko Y, Zdurowski S, Turner A, Sayenko D, Lu DC, Edgerton VR: **Weight bearing over-ground stepping in an exoskeleton with non-invasive spinal cord neuromodulation after motor complete paraplegia.** *Front Neurosci* 2017, **11**:333 <http://dx.doi.org/10.3389/fnins.2017.00333>.
49. Jeffrey-Gauthier R, Josset N, Bretzner F, Leblond H: **Facilitation of locomotor spinal networks activity by buspirone after a complete spinal cord lesion in mice.** *J Neurotrauma* 2018, **35**:2208-2221 <http://dx.doi.org/10.1089/neu.2017.5476>.
- Animal study providing a basis for the use of Buspirone in clinical trials on patients.
50. Minassian K, Hofstoetter US, Dzeladini F, Guertin PA, Ijspeert A: **The human central pattern generator for locomotion: does it exist and contribute to walking?** *Neuroscientist* 2017, **23**:649-663 <http://dx.doi.org/10.1177/1073858417699790>.
51. Radhakrishna M, Steuer I, Prince F, Roberts M, Mongeon D, Kia M, Dyck S, Matte G, Vaillancourt M, Guertin PA: **Double-blind, placebo-controlled, randomized phase I/IIa study (safety and efficacy) with buspirone/levodopa/carbidopa (Spinalon™) in subjects with complete AIS A or motor-complete AIS B spinal cord injury.** *Curr Pharm Des* 2017, **23**:1789-1804 <http://dx.doi.org/10.2174/1381612822666161227152200>.
- The first clinical trial using Spinalon™ showing EMG activity accompanied by locomotor-like characteristics with rhythmic and bilateral alternating bursts. This paper serves as a starting point for developing pharmacotherapy that is effective in a larger proportion of patients.
52. Leszczyńska AN, Majczyński H, Wilczyński GM, Stawińska U, Cabaj AM: **Thoracic hemisection in rats results in initial recovery followed by a late decrement in locomotor movements, with changes in coordination correlated with serotonergic innervation of the ventral horn.** *PLoS One* 2015, **10**:e0143602 <http://dx.doi.org/10.1371/journal.pone.0143602>.
53. Saruhashi Y, Young W, Perkins R: **The recovery of 5-HT immunoreactivity in lumbosacral spinal cord and locomotor function after thoracic hemisection.** *Exp Neurol* 1996, **139**:203-213 <http://dx.doi.org/10.1006/exnr.1996.0094>.
54. Saruhashi Y, Matsusue Y, Fujimiya M: **The recovery of 5-HT transporter and 5-HT immunoreactivity in injured rat spinal cord.** *Arch Orthop Trauma Surg* 2009, **129**:1279-1285 <http://dx.doi.org/10.1007/s00402-008-0754-z>.
55. Zuchner M, Kondratskaya E, Sylte CB, Glover JC, Boulland JL: **Rapid recovery and altered neurochemical dependence of locomotor central pattern generation following lumbar neonatal spinal cord injury.** *J Physiol* 2018, **596**:281-303 <http://dx.doi.org/10.1113/JP274484>.
56. Ganzer PD, Beringer CR, Shumsky JS, Nwaobasi C, Moxon KA: **Serotonin receptor and dendritic plasticity in the spinal cord mediated by chronic serotonergic pharmacotherapy combined with exercise following complete SCI in the adult rat.** *Exp Neurol* 2018, **304**:132-142 <http://dx.doi.org/10.1016/j.expneurol.2018.03.006>.
- Authors suggest a critical role of 5-HT and training in promoting neural plasticity. Their results support the idea that the activation of 5-HT<sub>1A</sub> receptors induces synaptic and structural plasticity. They present evidence that the combination of 5-HT + Bike therapy had a greater impact on spinal plasticity compared to either 5-HT or Bike alone, suggesting that these therapies may act synergistically when administered in combination. Therefore, combination therapies may be needed to promote significant locomotor recovery following severe SCI.
57. Gackiere F, Vinay L: **Serotonergic modulation of post-synaptic inhibition and locomotor alternating pattern in the spinal cord.** *Front Neural Circuits* 2014, **8**:102 <http://dx.doi.org/10.3389/fncir.2014.00102>.
58. Stawińska U, Majczyński H, Dai Y, Jordan LM: **The upright posture improves plantar stepping and alters responses to serotonergic drugs in spinal rats.** *J Physiol* 2012, **590**:1721-1736 <http://dx.doi.org/10.1113/jphysiol.2011.224931>.
59. Chopek JW, Sheppard PC, Gardiner K, Gardiner PF: **Serotonin receptor and KCC2 gene expression in lumbar flexor and extensor motoneurons posttransection with and without**

- passive cycling.** *J Neurophysiol* 2015, **113**:1369-1376 <http://dx.doi.org/10.1152/jn.00550.2014>.
60. Miazga K, Fabczak H, Joachimiak E, Zawadzka M, Krzemien-Ojak L, Bekisz M, Bejrowska A, Jordan LM, Stawińska U: **Intraspinal grafting of serotonergic neurons modifies expression of genes important for functional recovery in paraplegic rats.** *Neural Plast* 2018, **2018**:4232706 <http://dx.doi.org/10.1155/2018/4232706>.
  61. Bos R, Sadlaoud K, Boulenguez P, Buttigieg D, Liabeuf S, Brocard C, Haase G, Bras H, Vinay L: **Activation of 5-HT<sub>2A</sub> receptors upregulates the function of the neuronal K-Cl cotransporter KCC2.** *Proc Natl Acad Sci U S A* 2013, **110**:348-353 <http://dx.doi.org/10.1073/pnas.1213680110>.  
The first evidence that 5-HT controls the K-Cl cotransporter KCC2 and thereby influences inhibitory transmission in GABAergic interneurons.
  62. Boulenguez P, Liabeuf S, Bos R, Bras H, Jean-Xavier C, Brocard C, Stil A, Darbon P, Cattaert D, Delpire E, Marsala M, Vinay L: **Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury.** *Nat Med* 2010, **16**:302-307 <http://dx.doi.org/10.1038/nm.2107>.
  63. Tashiro S, Shinozaki M, Mukaino M, Renault-Mihara F, Toyama Y, Liu M, Nakamura M, Okano H: **BDNF induced by treadmill training contributes to the suppression of spasticity and allodynia after spinal cord injury via upregulation of KCC2.** *Neurorehabil Neural Repair* 2015, **29**:677-689 <http://dx.doi.org/10.1177/1545968314562110>.
  64. Tysseling VM, Klein DA, Imhoff-Manuel R, Manuel M, Heckman CJ, Tresch MC: **Constitutive activity of 5-HT<sub>2C</sub> receptors is present after incomplete spinal cord injury but is not modified after chronic SSRI or baclofen treatment.** *J Neurophysiol* 2017, **118**:2944-2952 <http://dx.doi.org/10.1152/jn.00190.2017>.
  65. Bellardita C, Caggiano V, Leiras R, Caldeira V, Fuchs A, Bouvier J, Low P, Kiehn O: **Spatiotemporal correlation of spinal network dynamics underlying spasms in chronic spinalized mice.** *eLife* 2017, **6** <http://dx.doi.org/10.7554/eLife.23011>.
  66. Zhang M: In *Normal Distribution and Plasticity of Serotonin Receptors After Spinal Cord Injury and Their Impacts on Motor Outputs*. Edited by Fuller H, Gates M. IntechOpen Limited; 2016 <http://dx.doi.org/10.5772/63759>.
  67. Fields DP, Mitchell GS: **Spinal metaplasticity in respiratory motor control.** *Front Neural Circuits* 2015, **9**:2 <http://dx.doi.org/10.3389/fncir.2015.00002>.
  68. Fields DP, Mitchell GS: **Divergent cAMP signaling differentially regulates serotonin-induced spinal motor plasticity.** *Neuropharmacology* 2017, **113**:82-88 <http://dx.doi.org/10.1016/j.neuropharm.2016.09.018>.
  69. Fields DP, Springborn SR, Mitchell GS: **Spinal 5-HT<sub>7</sub> receptors induce phrenic motor facilitation via EPAC-mTORC1 signaling.** *J Neurophysiol* 2015, **114**:2015-2022 <http://dx.doi.org/10.1152/jn.00374.2015>.
  70. Hayes HB, Jayaraman A, Herrmann M, Mitchell GS, Rymer WZ, Trumbower RD: **Daily intermittent hypoxia enhances walking after chronic spinal cord injury: a randomized trial.** *Neurology* 2014, **82**:104-113 <http://dx.doi.org/10.1212/01.WNL.0000437416.34298.43>.  
The first demonstration that intermittent hypoxia, which exerts its influence by altering 5-HT effects on relevant neurons, and enhances locomotor recover after spinal cord injury.
  71. Kondaurova EM, Bazovkina DV, Naumenko VS: **5-HT<sub>1A</sub>/5-HT<sub>7</sub> receptor interplay: chronic activation of 5-HT<sub>7</sub> receptors decreases the functional activity of 5-HT<sub>1A</sub> receptor and its content in the mouse brain.** *Mol Biol (Mosk)* 2017, **51**(1):157-165 <http://dx.doi.org/10.7868/S0026898416060100>.
  72. Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG: **Interplay between serotonin 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptors in depressive disorders.** *CNS Neurosci Ther* 2014, **20**:582-590 <http://dx.doi.org/10.1111/cns.12247>.
  73. Renner U, Zeug A, Woehler A, Niebert M, Dityatev A, Dityateva G, Gorinski N, Guseva D, Abdel-Galil D, Frohlich M *et al.*: **Heterodimerization of serotonin receptors 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> differentially regulates receptor signalling and trafficking.** *J Cell Sci* 2012, **125**:2486-2499 <http://dx.doi.org/10.1242/jcs.101337>.
  74. Borroto-Escuela DO, Carlsson J, Ambrogini P, Narvaez M, Wydra K, Tarakanov AO, Li X, Millon C, Ferraro L, Cuppini R *et al.*: **Understanding the role of GPCR heteroreceptor complexes in modulating the brain networks in health and disease.** *Front Cell Neurosci* 2017, **11**:37 <http://dx.doi.org/10.3389/fncel.2017.00037>.
  75. Santello M, Bisco A, Neviau NE, Lacivita E, Leopoldo M, Neviau T: **Brain-penetrant 5-HT<sub>7</sub> receptor agonist LP-211 reduces the sensory and affective components of neuropathic pain.** *Neurobiol Dis* 2017, **106**:214-221 <http://dx.doi.org/10.1016/j.nbd.2017.07.005>.
  76. Naumenko VS, Bazovkina DV, Kondaurova EM, Zubkov EA, Kulikov AV: **The role of 5-HT<sub>2A</sub> receptor and 5-HT<sub>2A</sub>/5-HT<sub>1A</sub> receptor interaction in the suppression of catalepsy.** *Genes Brain Behav* 2010, **9**:519-524 <http://dx.doi.org/10.1111/j.1601-183X.2010.00581.x>.
  77. Hensler JG, Truett KA: **Effect of chronic serotonin-2 receptor agonist or antagonist administration on serotonin-1A receptor sensitivity.** *Neuropsychopharmacology* 1998, **19**:354-364 [http://dx.doi.org/10.1016/S0893-133X\(98\)00037-2](http://dx.doi.org/10.1016/S0893-133X(98)00037-2).
  78. Valdez M, Burke TF, Hensler JG: **Selective heterologous regulation of 5-HT<sub>1A</sub> receptor-stimulated 35S GTPgammaS binding in the anterior cingulate cortex as a result of 5-HT<sub>2</sub> receptor activation.** *Brain Res* 2002, **957**:174-182.
  79. Zhang Y, D'Souza D, Raap DK, Garcia F, Battaglia G, Muma NA, Van de Kar LD: **Characterization of the functional heterologous desensitization of hypothalamic 5-HT(1A) receptors after 5-HT(2A) receptor activation.** *J Neurosci* 2001, **21**:7919-7927.
  80. Zhang Y, Gray TS, D'Souza DN, Carrasco GA, Damjanoska KJ, Dudas B, Garcia F, Zainelli GM, Sullivan Hanley NR, Battaglia G *et al.*: **Desensitization of 5-HT<sub>1A</sub> receptors by 5-HT<sub>2A</sub> receptors in neuroendocrine neurons in vivo.** *J Pharmacol Exp Ther* 2004, **310**:59-66 <http://dx.doi.org/10.1124/jpet.103.062224>.
  81. Basura GJ, Zhou SY, Walker PD, Goshgarian HG: **Distribution of serotonin 2A and 2C receptor mRNA expression in the cervical ventral horn and phrenic motoneurons following spinal cord hemisection.** *Exp Neurol* 2001, **169**:255-263 <http://dx.doi.org/10.1006/exnr.2001.7682>.
  82. Grinde E, Herrick-Davis K: **Class A GPCR: serotonin receptors.** In *G-Protein-Coupled Receptor Dimers*. Edited by Herrick-Davis K, Milligan G, Giovanni GD. Cham: Springer; 2017:467-475 [http://dx.doi.org/10.1007/978-3-319-60174-8\\_19](http://dx.doi.org/10.1007/978-3-319-60174-8_19).
  83. Pxinios G: *The Rat Nervous System*. New York: Academic Press; 1995.
  84. Jordan LM, Schmidt BJ: **Propriospinal neurons involved in the control of locomotion: potential targets for repair strategies?** *Prog Brain Res* 2002, **137**:125-139.